DBVTHIGH SIGNALFINANCIAL10-K

DBVT's outstanding shares more than doubled from 137M to 296M while current liabilities surged 86% and net losses widened to $147M, indicating significant dilution and deteriorating financial position despite advancing toward BLA submission.

The massive 116% increase in outstanding shares represents severe dilution for existing shareholders, likely from equity raises to fund operations. Combined with exploding current liabilities and widening losses, this suggests the company is burning through cash rapidly as it approaches its critical BLA filing milestone for Viaskin Peanut Patch.

Comparing 2026-03-26 vs 2025-04-11View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company under significant strain with current liabilities jumping 86% to $58M and operating losses expanding 26% to $147M, while R&D expenses increased 31% to $117M. Despite 36% revenue growth to $5.6M, the company appears to be funding operations through dilutive equity raises (evidenced by the share count doubling) and has dramatically reduced capital expenditures by 77%. The overall trajectory suggests mounting financial pressure as DBVT races toward its pivotal BLA submission deadline in the first half of 2026.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+86.4%
$31.1M→$58.0M

Current liabilities surged 86.4% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
-77.2%
$2.3M→$532K

Capex reduced 77.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
+69.7%
$38.3M→$64.9M

Liabilities grew 69.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Debt
Balance Sheet
-59.7%
$1.3M→$510K

Debt reduced 59.7% — deleveraging strengthens balance sheet and reduces financial risk.

Revenue
P&L
+35.8%
$4.2M→$5.6M

Strong top-line growth of 35.8% — accelerating demand or successful expansion into new markets.

R&D Expense
P&L
+30.6%
$89.3M→$116.7M

R&D investment increased 30.6% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-29%
-$113.9M→-$146.9M

Net income declined 29% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-26.1%
-$116.6M→-$147.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-16%
-$104.5M→-$121.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-04-11
ADDED
As of March 25, 2026, the registrant had 296,042,447 ordinary shares, nominal value 0.10 per share, outstanding.
F - 3 Currently, we do not have commercial-ready marketing and sales infrastructure.
If we are not able to comply with the applicable continued listing requirements or standards of the Nasdaq Capital Market ( Nasdaq ) our ADSs could be delisted.
We believe Viaskin technology may offer convenient, non-invasive immunotherapy to patients.
Our most advanced product candidate is Viaskin Peanut Patch, which has been evaluated as a potential therapy for children with peanut allergy in twelve completed clinical trials, including five Phase 2 trials and five completed Phase 3 trials.
The Company plans a BLA submission in the first half of 2026 for Viaskin Peanut Patch as a potential treatment for children four to seven years old.
The Company also has an ongoing Phase 3 supplementary safety study of Viaskin Peanut patch in peanut-allergic toddlers ages one through three.
Conditional on successful completion of this safety study, the Company plans a BLA submission in the second half of 2026 for children ages one to three.
The Company has earlier-stage food allergy programs including Viaskin Milk and other autoimmune inflammatory diseases.
Commercial Opportunity The Company is developing launch plans, subject to FDA approval of our product candidate, that are focused on addressing the unmet needs of patients, their caregivers, physicians, and payers.
REMOVED
As of April 10, 2025, the registrant had 136,948,872 ordinary shares, nominal value 0.10 per share, outstanding.
Currently, we do not have commercial-ready marketing and sales infrastructure.
If we are not able to comply with the applicable continued listing requirements or standards of the Nasdaq Capital Market, or Nasdaq, our ADSs could be delisted.
We believe Viaskin may offer convenient, , non-invasive immunotherapy to patients.
Our most advanced product candidate is Viaskin Peanut, which has been evaluated as a potential therapy for children with peanut allergy in eleven clinical trials, including four Phase 2 trials and four completed Phase 3 trials.
We also have an ongoing Phase 3 trial of Viaskin Peanut in children ages four to seven with peanut allergy, as well as one planned Phase 3 supplementary safety studies, in peanut-allergic toddlers, ages one through three.
We have earlier-stage food allergy programs including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Food allergen-specific approaches include epicutaneous immunotherapy, or EPIT, oral immunotherapy, or OIT, (both with and without adjunctive therapies), and sublingual immunotherapy, or SLIT.
Xolair (omalizumab), an anti-immunoglobulin E (IgE) antibody was recently approved by the FDA for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.
For example, in the case of respiratory allergies, symptomatic and maintenance allergy treatments, such as antihistamines, bronchodilators and corticosteroids, are available and all among the most widely used treatments in the world.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →